These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21906599)

  • 21. Enhancing efficiency and quality of statistical estimation of immunogenicity assay cut points through standardization and automation.
    Su C; Zhou L; Hu Z; Weng W; Subramani J; Tadkod V; Hamilton K; Bautista A; Wu Y; Chirmule N; Zhong ZD
    J Immunol Methods; 2015 Oct; 425():88-96. PubMed ID: 26130368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points.
    Devanarayan V; Smith WC; Brunelle RL; Seger ME; Krug K; Bowsher RR
    AAPS J; 2017 Sep; 19(5):1487-1498. PubMed ID: 28733862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development.
    Mikulskis A; Yeung D; Subramanyam M; Amaravadi L
    J Immunol Methods; 2011 Feb; 365(1-2):38-49. PubMed ID: 21130095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The significance of repeat testing in Turkish blood donors screened with HBV, HCV and HIV immunoassays and the importance of S/CO ratios in the interpretation of HCV/HIV screening test results and as a determinant for further confirmatory testing.
    Acar A; Kemahli S; Altunay H; Kosan E; Oncul O; Gorenek L; Cavuslu S
    Transfus Med; 2010 Jun; 20(3):152-9. PubMed ID: 20059750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies.
    Stubenrauch K; Wessels U; Essig U; Vogel R; Schleypen J
    J Pharm Biomed Anal; 2010 Jun; 52(2):249-54. PubMed ID: 20083366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Statistical methods of screening cut point determination in immunogenicity studies.
    Shen M; Dai T
    Bioanalysis; 2021 Apr; 13(7):551-563. PubMed ID: 33755515
    [No Abstract]   [Full Text] [Related]  

  • 27. Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA.
    Smith HW; Butterfield A; Sun D
    Regul Toxicol Pharmacol; 2007 Dec; 49(3):230-7. PubMed ID: 17869396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity of biological therapeutics: from assay to patient.
    Krieckaert C; Rispens T; Wolbink G
    Curr Opin Rheumatol; 2012 May; 24(3):306-11. PubMed ID: 22388644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing immunogenicity in the presence of excess protein therapeutic using immunoprecipitation and quantitative mass spectrometry.
    Neubert H; Grace C; Rumpel K; James I
    Anal Chem; 2008 Sep; 80(18):6907-14. PubMed ID: 18702532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics.
    Gupta S; Indelicato SR; Jethwa V; Kawabata T; Kelley M; Mire-Sluis AR; Richards SM; Rup B; Shores E; Swanson SJ; Wakshull E
    J Immunol Methods; 2007 Apr; 321(1-2):1-18. PubMed ID: 17307199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity issues in drug development.
    Swanson SJ
    J Immunotoxicol; 2006 Sep; 3(3):165-72. PubMed ID: 18958697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Scientific and regulatory considerations on the immunogenicity of biologics.
    Shankar G; Shores E; Wagner C; Mire-Sluis A
    Trends Biotechnol; 2006 Jun; 24(6):274-80. PubMed ID: 16631266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.
    Shankar G; Devanarayan V; Amaravadi L; Barrett YC; Bowsher R; Finco-Kent D; Fiscella M; Gorovits B; Kirschner S; Moxness M; Parish T; Quarmby V; Smith H; Smith W; Zuckerman LA; Koren E
    J Pharm Biomed Anal; 2008 Dec; 48(5):1267-81. PubMed ID: 18993008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics.
    Wullner D; Zhou L; Bramhall E; Kuck A; Goletz TJ; Swanson S; Chirmule N; Jawa V
    Clin Immunol; 2010 Oct; 137(1):5-14. PubMed ID: 20708973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity of protein therapeutics.
    De Groot AS; Scott DW
    Trends Immunol; 2007 Nov; 28(11):482-90. PubMed ID: 17964218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of bias in MoM values on patient risk and screening performance for Down syndrome.
    Nix B; Wright D; Baker A
    Prenat Diagn; 2007 Sep; 27(9):840-5. PubMed ID: 17600858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. False positives in plasma ammonia measurement and their clinical impact in a pediatric population.
    Maranda B; Cousineau J; Allard P; Lambert M
    Clin Biochem; 2007 May; 40(8):531-5. PubMed ID: 17408610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immuno-PCR assays for immunogenicity testing.
    Spengler M; Adler M; Jonas A; Niemeyer CM
    Biochem Biophys Res Commun; 2009 Sep; 387(2):278-82. PubMed ID: 19577544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of in-study cut points to enable appropriate interpretation of clinical immunogenicity results.
    Brumm J; Peng K
    Bioanalysis; 2019 Sep; 11(17):1539-1541. PubMed ID: 31208203
    [No Abstract]   [Full Text] [Related]  

  • 40. How to predict and prevent the immunogenicity of therapeutic proteins.
    Schellekens H
    Biotechnol Annu Rev; 2008; 14():191-202. PubMed ID: 18606364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.